We read 455 filings today. Here are the ones worth your time.
326 Form 4129 8-K8 Buys101 Sells
CVS's Larry Robbins just moved $317.5 million out of his position. That's the kind of number that makes you stop scrolling.
Meanwhile, five insiders walked in with their own money: CDW's Leahy, two NCLH executives (Cohen and Cil), and two BSX directors (Habiger and Ludwig) all bought. Across 455 filings, that's 8 buys against 101 sells.
CVS's chairman sold $317.5M this week. Discretionary. Not a scheduled 10b5-1 sale, which means Larry Robbins picked the timing himself. He unloaded 41.1% of his position at $93.32, just under the 52-week high of $98. The stock's been range-bound all year, flat at 0% YTD, but Robbins took his exit near the top of that range.
Here's the conflict: CVS just announced a $40B acquisition of Signify Health four months ago, positioning itself as a vertically integrated healthcare giant. The chairman reduces his stake by nearly half while the company doubles down on expansion. He's been on the board since 2022. This is his first major exit. The filing shows discretionary. The timing shows something else.
Director Leahy just put $499K into CDW at $107, buying it discretionary while the stock sits 43% below its 52-week high. She added 2.4% to her position as the stock flatlines for the year despite tech hardware rallying. Her timing looks deliberate, buying near the low end of the range while competitors trade at all-time highs.
Director Jonathan Cohen just bought $475K of Norwegian Cruise Line at $16, a dollar above the 52-week low. The stock has been cut in half from its February peak as the company faces a fraud investigation. Cohen now owns 43.5% more shares than he did yesterday, and this was his call, not a pre-planned trade.
Board member Jose Cil dropped $451K into Norwegian Cruise at $16, just above the 52-week low of $15. Discretionary buy, not pre-planned. The stock is down 41% from its peak while the company faces a fraud investigation from Schall Law Firm. Cil now has a third of his holdings purchased at this level.
Director Habiger bought $251K of BSX at $57, discretionary and not pre-planned. The stock has cratered 48% from its 52-week high of $110 despite the company just spending $1.5B to expand in aortic stenosis. His purchase represents 28% of his total holdings, a meaningful bet at what could be a floor.
Board member Ludwig just bought $203K of BSX at $57, discretionary and near the 52-week low of $53. The stock has cratered 48% from its $110 peak despite the company just dropping $1.5B to expand in aortic stenosis. Ludwig increased his stake by 12% while the market treats this like a failed trade.
BSX $57.15 . 52w: $53-$110 . +0% YTD
THE TAPE
MPWR
Maurice Sciammas sells $18.7M of MPWR
HAL
Van Beckwith sells $8.2M of HAL
ABNB
Joseph Gebbia sells $7.3M of ABNB
AIZ
CFO Keith Meier sells $6.4M of AIZ
AFL
Japan Post Holdings Co., Ltd sells $5.9M of AFL
HSY
Hershey Trust CO Trustee IN Trust For Milton Hershey School sells $5.7M of HSY
AFL
Japan Post Holdings Co., Ltd sells $4.9M of AFL
KEY
Of Bank sells $4.7M of KEY
HSY
Hershey Trust CO Trustee IN Trust For Milton Hershey School sells $3.8M of HSY
Tractor Supply tapped its $1.5B revolving credit facility, drawing down the full amount in one go. The rural retailer's stock is already down 50% from its 52-week high at $32, suggesting this cash raise is about shoring up liquidity rather than funding expansion. With shares near decade lows and credit lines getting maxed out, the company is clearly in defensive mode.
Equity Residential shuffled its executive suite, bringing in a new CFO while its former finance chief moves to a different role. The REIT also amended its bylaws and disclosed other corporate updates in a kitchen-sink 8-K covering eight different items. EQR stock is flat on the year, trading near the middle of its 52-week range as investors digest the leadership changes.
AvalonBay signed a material agreement and issued an FD disclosure, suggesting a strategic transaction or financing move that required immediate public notice. The REIT is trading mid-range after a flat year, leaving room for either direction depending on the deal's terms. Watch for details in the exhibits, these dual filings typically mean capital deployment or asset sales that could reshape the portfolio or balance sheet.